Key facts
- Histofy’s last known valuation is $4.0M (May 2025).
- It has raised $1.8M; the latest was Early Stage VC ($1.1M) in May 2025.
- Notable investors include Innovate UK, Lumiares, National Institute for Health and Care Research, University of Warwick.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Histofy
- ·The full record, as it builds
Funding rounds
No funding rounds for Histofy are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Histofy
Developer of an artificial intelligence platform for computational pathology, designed to enable transparent and reproducible tissue analysis in clinical and research settings. The company's platform uses explainable AI for image segmentation, cellular quantification, and feature extraction, enabling pathology labs and healthcare providers with interpretable results, streamlined workflows, and improved diagnostic accuracy.
- Sector
- Healthcare
- HQ
- Coventry, United Kingdom
- Founded
- 2021
- Employees
- 10
- Website
- histofy.ai/
- Ownership
- Privately Held (backing)
Histofy doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Histofy shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Histofy in its N-PORT filings yet. We sweep new filings monthly.